Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF10 + Chemotherapy in Unresectable Pancreatic Cancer
NCT03252808Phase 1Active, not recruiting
- Sponsor
- Takara Bio Inc.
- Start
- Sep 2017
- Primary completion
- Feb 2020
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of canerpaturev in pancreatic cancer (PC), sponsored by Takara Bio Inc. Primary endpoint: Dose Limiting Toxicity at 4 weeks. Started Sep 2017; status: active, not recruiting.
02
Drugs
canerpaturev
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03252808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03252808.